Company Management

You are here:

ChemoTech has a very competent management and Board of Directors with extensive expertise and substantial experience of medical research and clinical work, as well as of the international healthcare industry.

Lars Hedbys

Chairman of the Board of Directors

Born 1957. Chairman of the Board of Directors since 2020.

Independent in relation to the Company and its management but independent in relation to major shareholders..

Education and experience: M.Sc. Chemical Engineering, Chalmers University of Technology, Ph.D. Department of Pure and Applied Biochemistry, Lund Institute of Technology, University of Lund. Lars has 30 years’ experience from leading positions in life science companies. A large part of his career has involved research and development at for example AstraZeneca but Lars also has a vast experience in founding, running and developing companies in life science.

Current assignments: Chairman and co-founder of IAmPatient AB, Chairman of the board at Asgard Therapeutics AB, alternate board member of CanImGuide AB and Immodulate AB, board member of RhoVac AB (publ) and Cell Invent AB, and adjunct board member of Xintela AB.

Previous assignments (last five years): CEO of Idogen AB, Acting CEO of Pharmiva AB and Chairman of the Board of Directors of Lund Life Science Incubator.

Lars Hedbys holds 1,282 B-shares via company.

Mohan Frick

CEO and Founder

Born 1974. Member of the Board of Directors and CEO since 2015.

Not independent in relation to the Company and, being the Company´s largest shareholder, not independent in relation to major shareholders.

Education and experience: BA, Marketing, Management, Lund University. 20 years’ experience as market manager, sales manager and Board member of life science companies. Has among other things held positions in Arjo AB, Getinge, Navigator Communications, Insulution AB, OnMeD and SYSMEX.

Current assignments: Chairman of Scandinavian MediTech (Indian subsidiary), Fricks Property & Equity Invest AB.

Previous assignments (last five years): Member of the Board of Directors of Insulution AB 2009-2011, Onmed International 2012-March 2013, Onmed India Private Limited 2011-June 2014. Member of the Advisory Board for Billion Minds Foundation 2009-2014.

Mohan Frick holds 665,000 A-shares, 248,979 B-shares, direct or via company.

Ashim Purohit

Chairman of Scandinavian Meditech India Pvt Ltd

Born 1968. Chairman of Scandinavian Meditech India Pvt Ltd 2017.

Education and experience: Engineering Graduate with Diploma in Management & Marketing. 29 years’ experience including customer service, sales, product mgt, marketing & general mgt. Formative 14 years with Siemens Medical India, in India.

Current assignments: Own growth consulting, leadership mentoring & entrepreneurship guidance practice – for GTM approach in India.  Director of Advisory Board at AGD Biomedicals Pvt Ltd. Anchor Mentor & Advisor at Sensivision Health Technologies.

Previous assignments (last five years): Founding President & CEO of Getinge’s Medical Systems (MAQUET) in India.

Rolf Ehrnström

Member of the Board of Directors

Born 1953. Member of the Board of Directors since 2020.

Independent of the Company and independent of major shareholders.

Education and experience: Royal Institute of Technology; MS in Biochemistry & Biotechnology. Extensive experience from Life Science Industry. Scientific and Product Development management roles in LKB/Pharmacia Biotech/Amersham-Pharmacia Biotech. Co-founder and VP R&D of Gyros AB, CVP/CSO of Dako-Agilent A/S, Boardmember of Biomonitor A/S.

Current assignments: CSO of Immunovia AB, Boardmember of Gradientech AB, Boardmember of Fluimedix A/S,  CEO and owner of Reomics AB, Partner in Ventac Partners, Partner in Ventac Capital

Previous assignments (last five years): –

Rolf Ehrnström holds 20,000 B-shares direct or via company.

Robin Sukhia

Member of the Board of Directors

Born 1973. Member of the Board of Directors since 2020

Independent of the Company and independent of major shareholders.

Education and experience: Bachelor of Science in Business Administration from the State University of New York. Has also studied at Uppsala University’s renowned Institution for Peace and Conflict Studies for his own interest.Robin Sukhia has worked with India since 1996. Through a Swedish Venture Capital firm, he was one of the pioneers in northern Europe to invest into India. He has held board positions in India and Sweden and since 2005.

Current assignments:  Secretary General and President of the Sweden-India Business Council (SIBC), Secretariat to ISBLRT – India Sweden Business Leaders’ Roundtable

Previous assignments: Special Advisor at Risk Mitigation firm Vesper Group, which is Swedens primary company on advising corporates on security and protection in high risk countries.

Robin Sukhia holds 14,000 B-shares.

Eva Ståhl Wernersson

QM/RA Director

Born 1959.

Education and experience: Master of Science in Chemical Engineering, 1985, Doctoral of philosophy in Engineering, 1997 at Lund University. Close to 40 years´ experience from medical technology, biotech and health care companies in roles such as Director Environmental Laboratories, Quality Director and QA/RA specialist consultant. She has held positions in Pharmviva AB, Camurus AB, Sandberg Development and now has her own consulting business Astrad AB.

Eva Ståhl Wernersson holds 12,000 B-shares.

Bengt Engström

Member of the Board of Directors

Born 1953. Member of the Board of Directors since 2020.

Independent of the Company and independent of major shareholders.

Education and experience: Degree from Royal Institute of Technology (KTH) in Stockholm. Formerly President Whirlpool Europe, CEO Duni AB, President Fujitsu Nordic and Director at Bofors AB.

Current assignments: Chairman of QleanAir AB and Nordic Flanges AB. Board member of Directors of Bure Equity AB, Scanfil OY, ScandiNova Systems AB, KTH Executive School AB, Real Holding AB. CEO of BEngström AB and BEngström Förvaltning AB.

Previous assignments (last five years): Opticos AB, Scandinavian Executive AB, Advania AB, Prevas AB, Crem International AB, Chambers Group AB, Scanfil Sweden AB and Partnertech AB.

Bengt Engström holds 43,000 B-shares direct or via company.

Anders Johnsson

Business Unit Director Animal Care

Born 1963.

Education and experience: M.Sc. Computer Engineering, Lund Institute of Technology. 30 years in leading management-, sales- and marketing positions within the Yggdrasil Group and the Malmöhus Invest Group and others. 10 years of experience in the development and commercialization of electrochemo- and electrogene therapy devices.

Current assignments: Member of the board at Bamboo Group AB, Malmo, Sweden (Yggdrasil Group), Founder and owner of XCell Solution AB, Malmö, Sweden.

Previous assignments (last five years): Chairman of Bamboo Solutions Corporation, Reston VA, USA (Yggdrasil Group), Chairman of Yggdrasil Holding PTE. LTD., Singapore and Yggdrasil Vietnam LLC., Vietnam, Chairman of Böhmer Audio AB, Lund, Sweden.

Urban Widen


Born 1957.

Education and experience: GIH University, Karolinska Institute, Stockholm, Sweden, Master in Physical Science & Public Health. INSEAD, IEP International Executive Program, Fontainebleau, France. MBA, LifeScience Micro MBA MasterClass, GLC Europe. More than 25-year experience in the area of Life Science and about 20 years as CEO/General Manager. A risk taker, who looks for initiatives, and deliver, required results or more. Recognized strengths in entrepreneurship, increasing productivity, team building, passionate to “ennoble” employees to new levels. Mastering Go-to-Markets models for novel products/services within new landscapes.

Current assignments:Chairman of Lumito AB (publ) Sweden, Chairman of Stockholm 3 Inc, Canada

Previous assignments (last five years): Lumito AB (publ) CEO (interim) 2020-2021, Indivior – Country Manager Nordics & Baltics 2018-2020 (interim), CEO Fürst Laboratories AB, Sweden2014-2018.

Martin Jerndal

Member of the Board of Directors

Born 1975. Member of the Board between august 2015 – June 2019 and again since May 2021.

Not independent in relation to the Company and being one of the Company´s largest shareholders, not independent in relation to major shareholders.

Education and experience:Master of Business and Science, Finance, Lund University. 20 years’ banking experience with main focus on market making and trading credit risk.

Current assignments: Working within family office.

Previous assignments (last five years): Execution Trader, Fixed Income, Robur, 2018-2020. Member of the Board, Scandinavian Chemotech AB, 2015-2019. Chief Dealer, Head of Credit Trading Sweden, Credit Trading and Complex Risk, Nordea, 2007-2017.

Martin Jerndal holds 582,695 B-shares direct or indirect via closest family.